S-1: Callan JMB Files S-1 for Hexstone Resale, Reports Q2 Losses

Callan JMB Inc. filed an S-1 registration statement for the resale of up to 6 million shares by Hexstone Capital, LLC, while reporting significant revenue declines and increased net losses for the first half of 2025.

Summary

• Callan JMB Inc., a vertically integrated logistics and fulfillment company specializing in thermal management for the life sciences industry, filed an S-1 registration statement for the resale of up to 6,000,000 shares of common stock by Hexstone Capital, LLC.
• The company will not receive proceeds from Hexstone's resale but may receive up to $25,000,000 in gross proceeds from future sales of common stock to Hexstone under an Equity Line of Credit (ELOC) Purchase Agreement.
• Revenue for the six months ended June 30, 2025, decreased by 17% to $3,115,687 from $3,776,289 in the prior year, primarily due to decreased demand for emergency preparedness services.
• Net loss for the six months ended June 30, 2025, significantly widened to $(2,641,986) from $(193,609) in the same period of 2024, an increase of 1264%.
• Selling, general, and administrative expenses increased by 105% to $3,901,878 for the six months ended June 30, 2025, driven by IPO-related professional fees, IT support, and marketing.
• The company completed an Initial Public Offering (IPO) in February 2025, raising approximately $5.776 million gross ($4.7 million net) from the sale of 1,280,000 shares and an over-allotment of 164,000 shares at $4.00 per share.
• Customer concentration remains high, with the top three customers accounting for 76% of total revenues for the six months ended June 30, 2025.
• Management identified material weaknesses and significant deficiencies in internal controls over financial reporting, including insufficient staff for segregation of duties and reliance on a third-party accounting firm for GAAP compliance.
• The company recently expanded into India and Korea through subsidiaries and contractual partnerships, acknowledging the inherent risks of operating in foreign and emerging markets.

Sentiment

Score: 3

Explanation: The company faces significant financial headwinds with substantial revenue declines and widening losses, indicating operational challenges. While the ELOC provides a capital lifeline and strategic growth areas are identified, the current financial performance and internal control weaknesses present considerable risks. The IPO proceeds offer some liquidity, but the overall trend is negative.

Positives

• The company has a long history and recognized reputation for delivering swift, decisive, and reliable emergency response support for Fortune 500 firms, NATO, the UN, and government agencies.
• Proprietary Ship2Q ultraviolet disinfection process ensures fitness, thermal reliability, and cleanliness of system components, meeting cGMP and cGDP compliance standards.
• The Sentry cloud-based logistics operating platform integrates GPS and precise temperature diagnostics, providing real-time tracking and validation documentation for temperature-sensitive goods.
• Reusable packaging systems and a leasing model contribute to environmental sustainability by reducing waste and costs compared to traditional single-use packaging.
• The company has established strategic alliances with global shipping providers like FedEx, DHL, and UPS, which are expected to drive revenue growth.
• The ELOC Purchase Agreement with Hexstone Capital provides access to up to $25,000,000 in capital, offering a potential source of funding for general corporate purposes, debt repayment, capital expenditures, and operational expenses.
• The company is exploring expansion into new market opportunities, including GLP-1 drug transport, compounding pharmacies, and high-end food packaging, leveraging its existing thermal management expertise.

Negatives

• Revenue for the six months ended June 30, 2025, decreased by 17% to $3,115,687, and for the three months ended June 30, 2025, decreased by 16% to $1,666,309, primarily due to reduced demand for emergency preparedness services.
• Net loss significantly increased by 1264% to $(2,641,986) for the six months ended June 30, 2025, compared to $(193,609) in the prior year period.
• Gross profit decreased by 25% for the six months ended June 30, 2025, and by 33% for the three months ended June 30, 2025.
• Selling, general, and administrative expenses increased substantially by 105% for the six months ended June 30, 2025, due to IPO-related costs and increased marketing.
• The company experienced a 50% revenue decrease in 2024 compared to 2023, largely due to the waning COVID-19 pandemic and a significant customer temporarily suspending orders (approximately $4,000,000 impact).
• Management has identified material weaknesses and significant deficiencies in internal controls over financial reporting, including insufficient staff for segregation of duties and reliance on a third-party accounting firm.
• The company has a limited sales force, with the CEO historically serving as the principal marketing officer, which may negatively affect growth.
• The company does not have key man life insurance for its CEO, Wayne Williams, posing a risk in case of his death or disability.
• The company has exceeded the permissible number of shares to be issued under the 2024 Equity Incentive Plan by 200,000 share awards, requiring an amended Form S-8 filing.

Risks

• Rapid growth and limited operating history may lead to increased risks, uncertainties, expenses, and difficulties in evaluating prospects.
• Dependence on a holding company structure means reliance on distributions from operating subsidiaries, which could be limited by contractual or legal restrictions.
• Business is capital intensive, requiring ongoing cash outlays that may strain available capital and necessitate selling assets, incurring debt, or selling equity on unfavorable terms.
• Decreased availability or increased costs of key logistics and supply chain inputs, including third-party supplies of equipment and materials, could impact profitability.
• The rent-to-rent model involves significant upfront capital outlay for warehouse sourcing and renovation, ongoing maintenance needs, and risks of delayed service fee collection or mismatch in agreement terms.
• Risks associated with cold chain logistics services include product contamination, spoilage, tampering, or other quality control issues, potentially leading to liability for lost inventory or harm to consumers.
• Inability to successfully identify, source, and develop additional warehouse properties in a timely fashion could impair growth strategy.
• High customer concentration (top three customers accounted for 76% of revenue in H1 2025) means loss of a major customer could materially adversely affect the business.
• Inaccurate forecasts of customer demand could lead to inability to meet demand, lost revenue opportunities, or excess/obsolete equipment and inventory.
• Delays or interruptions in shipping due to factors outside of control (natural disasters, carrier error) could harm reputation and operating results.
• Need to raise substantial additional capital in the future, which could result in dilution to stockholders or restrictive debt covenants.
• Loss of executive team or inability to attract and retain highly skilled employees could materially harm the business.
• Management team has limited experience managing a public company, potentially diverting attention from day-to-day operations.
• Potential future acquisitions may not be successful, could divert management resources, and lead to significant dilution or use of available cash.
• Intense competition from local, regional, and national firms, some with greater resources, could adversely affect the business.
• Lack of adequate D&O insurance may make it difficult to attract and retain talented directors and officers and could result in substantial indemnification costs.
• Changes in government regulation (FDA, state agencies, CDC, OSHA, DOT, IATA, ICAO) could adversely affect operations, require costly changes, or prevent marketability of solutions.
• Reliance on critical information systems (Sentry platform) exposes the company to risks of cyberattacks, data incidents, and breaches, potentially leading to reputational harm, liabilities, and increased costs.
• Expansion into India and Korea exposes the company to political and economic instability, legal and judicial uncertainty, currency and financing risks, cultural/operational challenges, and heightened compliance obligations.
• The sale of shares by the Selling Stockholder (Hexstone), or the perception of such sales, could cause the stock price to decrease due to dilution and discounted purchase prices.
• The common stock may experience rapid and substantial price volatility, unrelated to actual performance, due to a relatively small public float.
• The company does not intend to pay dividends for the foreseeable future, meaning capital appreciation is the only way for stockholders to realize gains.
• Potential for the company's securities to be considered a 'penny stock,' discouraging broker-dealers from effecting transactions.

Future Outlook

The company aims to leverage its core competitive strengths to grow service lines and maintain customer relationships, aspiring to be the premier provider of logistics and fulfillment services. It plans to expand into additional market opportunities, including GLP-1 drug transport, compounding pharmacies, and high-end food packaging, by adapting its Sentry monitoring and Ship2Q systems. The strategy also involves continuous efforts to increase efficiency, reduce costs through technology and process improvements, and foster innovation, including artificial intelligence and predictive technology, to enhance productivity and customer experience. The company expects its operations to vary seasonally, with higher revenue in the third and fourth calendar quarters.

Management Comments

• We view our solutions as disruptive to the older technologies of dry ice and liquid nitrogen, in that our solutions are comprehensive and combine our competencies in configurations that are customized to our clients requirements.
• Our team is committed to identifying opportunities to cross-sell among and across our divisions which we expect will continue to drive additional revenue for our Company.
• In the future, we hope to expand our business to include support for glucagon-like peptide receptor-1 agonist (GLP-1) transport, compounding pharmacies and high-end food packaging.
• We believe that our system can minimize the risk of spoilage, contamination, and other issues that can compromise drug effectiveness and food safety.
• With Sentry monitoring, we intend to provide customers with confidence that their drug and food shipments will arrive in the same pristine condition as when they were dispatched, safeguarding patient and consumer health and satisfaction.
• We continually seek to increase efficiency and reduce costs through enhanced technology, process improvements and strategic expense management.
• We believe that making technological investments that increase the value of our services delivered to our customers pays off in a variety of ways including growth, retention, profitability, and overall customer experience.

Industry Context

The company operates in a rapidly growing segment of the logistics industry focused on temperature-sensitive packaging and shipping of biological materials. This segment is experiencing increased expenditures for value-added packaging due to globalization and the introduction of pharmaceutical products requiring continuous cryogenic refrigeration. The company anticipates the introduction of global industry standards and regulations requiring more comprehensive tracking and validation of shipping temperatures. Its solutions are positioned as disruptive alternatives to older technologies like dry ice and liquid nitrogen, offering comprehensive, reliable, and economic options for various life science markets, including cell-based therapies, gene/stem cell biotechnology, vaccine production, and specialty drug distribution. The company is also targeting emerging markets like GLP-1 drug transport and high-end food packaging, aligning with broader trends in specialized logistics.

Comparison to Industry Standards

• The company's Ship2Q process meets cGMP (good current manufacturing practices) and cGDP (good current distribution practices) compliance standards, which are critical for highly regulated industries like life sciences, aligning with global benchmarks for product integrity.
• The Sentry system's integration of GPS and precise temperature diagnostics for continuous monitoring aims to exceed typical industry standards by providing 'zero bench time' and fully documented chain-of-custody and chain-of-condition, which is crucial for scientific and regulatory purposes.
• The company's reusable packaging systems and leasing model offer an environmentally sustainable alternative to traditional single-use packaging, positioning it favorably against competitors that may not prioritize sustainability.
• While the company faces robust competition from local, regional, and national firms, it believes no single competitor directly competes with its full suite of vertically integrated offerings, suggesting a unique market position compared to more specialized industry players.
• The company's long-standing relationships with Fortune 500 firms, the City of Chicago, NATO, and the UN demonstrate a track record of meeting stringent requirements in highly regulated environments, comparable to leading industry service providers.

Management Changes

Corporate Governance

Legal Proceedings

• A demand letter was received in May 2024 alleging breach of a Customer Service Agreement with a vendor, claiming $507,573. The company asserted it owed $85,000.
• In February 2025, the parties agreed to settle the matter for $240,800, which was paid on February 26, 2025. The company increased its accrued expenses by $155,800 as of December 31, 2024, to reflect the settled amount.

Related Party Transactions

• The company leases its executive offices, a warehouse, other warehouse equipment, and a box truck from Warehouse Asset Management, which is majority-owned by Messrs. Williams (CEO) and Croyle (CMO), for $15,425 per month.
• The company pays $9,800 per month to Outlaw Run Ranch (owned by Mr. Williams) for rent expenses.
• Advances of $18,669 were made to a director during 2024, which were repaid in full in 2025.
• 100,000 stock options were awarded to the CEO's son as compensation for prior services, with 12,500 vested as of June 30, 2025.
• The company's predecessor entity received an advance of $110,736 from Health Hero America (owned by Mr. Williams) in 2022, which was repaid by June 30, 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from the ELOC Purchase Agreement with Hexstone Capital and potential future equity raises. The substantial net losses and revenue decline could negatively impact share price and investment value. The identified material weaknesses in internal controls also pose a risk to financial reporting reliability.
• **Employees**: The 2024 Equity Incentive Plan provides opportunities for equity awards, potentially boosting morale and retention, but the plan exceeding its share limit requires corrective action. The increase in personnel costs due to hiring additional staff in anticipation of the IPO suggests growth in the workforce.
• **Customers**: Benefit from the company's advanced thermal management solutions (Ship2Q, Sentry system) ensuring product integrity and timely response. However, high customer concentration means the loss of a major client could impact service stability. Expansion into new markets like GLP-1 transport and high-end food packaging could offer new service options.
• **Suppliers/Vendors**: The settlement of a lawsuit with a vendor for $240,800 indicates past disputes, but the resolution may help maintain vendor relationships. The company's reliance on third-party supplies and transportation services means disruptions or cost increases could affect service delivery.
• **Creditors**: The potential for up to $25 million in proceeds from the ELOC with Hexstone could improve liquidity and the ability to repay debt, reducing credit risk. However, the significant net losses and capital-intensive nature of the business highlight ongoing financial risk.

Next Steps

• File an amended Form S-8 to register additional shares to account for the overallotment under the 2024 Equity Incentive Plan.
• Continue to develop and refine disclosure controls and internal controls over financial reporting to address identified material weaknesses and significant deficiencies.
• Actively manage the ELOC Purchase Agreement with Hexstone Capital to draw down capital as needed for general corporate purposes, debt repayment, capital expenditures, and operational expenses.
• Focus on expanding into new market opportunities such as GLP-1 drug transport, compounding pharmacies, and high-end food packaging.
• Implement strategies to increase efficiency and reduce costs through enhanced technology, process improvements, and strategic expense management.
• Monitor and address customer concentration risk to diversify revenue streams.
• Address the challenges and risks associated with operating in emerging and foreign markets like India and Korea.

Key Dates

Recommendation

The company is in a critical transition phase, having recently completed an IPO and secured an equity line of credit, which provides much-needed capital. However, the significant decline in revenue and widening net losses for both the recent quarter and the full prior year are concerning. While the company operates in a growing niche (cold chain logistics for life sciences) and has a strong competitive position in emergency response, its financial performance is currently deteriorating. The identified material weaknesses in internal controls and high customer concentration add to the risk profile. A 'hold' recommendation is appropriate as investors should monitor whether the new capital infusion and strategic expansion efforts (GLP-1, food packaging, international markets) can reverse the negative financial trends and address operational inefficiencies. The stock's recent volatility and potential for dilution from Hexstone's resale also warrant caution rather than an immediate 'buy' or 'sell' decision.

Keywords

Cold Chain Logistics, Life Sciences Logistics, Thermal Management, Cryogenic Shipping, Emergency Response Logistics, Specialty Packaging, Sentry Monitoring, Ship2Q, Biopharmaceuticals Transport, Cell Therapies Logistics, Vaccine Distribution, SEC S-1 Filing, Equity Line of Credit, Hexstone Capital, Nasdaq CJMB, Supply Chain Technology, Healthcare Logistics, Pharmaceutical Logistics